Moreover, we assessed the effect of the inhibition of HSP70/HSF1 axis by the targeting of RAS-signalling pathway, demonstrating its efficacy in CLL cells. This evidence concerns the gene HSF1 and B-cell chronic lymphocytic leukemia.